OPKO Health, Inc. (NASDAQ:OPK - Free Report) - Equities research analysts at Zacks Research issued their FY2027 earnings estimates for shares of OPKO Health in a research report issued to clients and investors on Thursday, March 20th. Zacks Research analyst R. Department anticipates that the biotechnology company will post earnings of ($0.09) per share for the year. The consensus estimate for OPKO Health's current full-year earnings is ($0.25) per share.
OPKO Health (NASDAQ:OPK - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The company had revenue of $183.60 million during the quarter, compared to analyst estimates of $155.42 million.
A number of other equities research analysts have also weighed in on the stock. Barrington Research reiterated an "outperform" rating and set a $2.25 target price on shares of OPKO Health in a research note on Wednesday, March 12th. HC Wainwright reiterated a "buy" rating and set a $3.00 target price on shares of OPKO Health in a research note on Wednesday, March 19th. Finally, StockNews.com upgraded shares of OPKO Health from a "sell" rating to a "hold" rating in a research note on Monday, March 3rd.
View Our Latest Research Report on OPK
Shares of NASDAQ OPK opened at $1.80 on Monday. The firm has a market cap of $1.21 billion, a P/E ratio of -9.47 and a beta of 1.70. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The company has a 50 day moving average of $1.65 and a 200 day moving average of $1.57. OPKO Health has a twelve month low of $0.92 and a twelve month high of $2.04.
In related news, CEO Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock in a transaction dated Wednesday, January 15th. The stock was purchased at an average cost of $1.48 per share, for a total transaction of $740,000.00. Following the purchase, the chief executive officer now directly owns 213,036,477 shares of the company's stock, valued at approximately $315,293,985.96. This trade represents a 0.24 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders purchased 964,971 shares of company stock worth $1,493,692 in the last three months. Corporate insiders own 47.26% of the company's stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC increased its stake in shares of OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 11,089 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in OPKO Health by 75.3% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock worth $42,000 after buying an additional 12,417 shares during the period. Orion Portfolio Solutions LLC bought a new position in OPKO Health in the 3rd quarter worth $45,000. Cibc World Markets Corp bought a new position in OPKO Health in the 4th quarter worth $45,000. Finally, Zacks Investment Management bought a new position in OPKO Health in the 4th quarter worth $49,000. 64.63% of the stock is currently owned by hedge funds and other institutional investors.
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider OPKO Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OPKO Health wasn't on the list.
While OPKO Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.